

REMARKS

The claims have been amended in accord with the current rules in which underlining shows additions and strikethrough shows deletions. No new matter has been added.

The amendments to claims 11-13, 16 and 20 are merely editorial.


The amendments to claims 17, 20 and 22 correct a possible misunderstanding as to the changes the undersigned authorized in the examiner's amendment. Specifically, incorporation of mole % numerical ranges for the monomers present in claims 1 and 17, and narrowing the amount of (d) in claim 19 to distinguish it from claim 17, was authorized. But adding an additional component, monomer (d), which is merely a preferred embodiment and is totally unnecessary to patentability, was not authorized in claim 1. Applicants note that monomer (d) first appears in claims allowed claims 8 and 9, which were neither amended nor cancelled in the examiner's amendment. This indicates agreement, at the time, that monomer (d) should not have been added to claim 1.

Further, in claims 17 and 22, use of monomer (d) was clearly optional. Hence the only appropriate lower limit is zero. Again narrowing it is totally unnecessary to patentability and was not authorized.

Since the examiner's amendment restricts applicants to an invention far narrower than they have enabled and claimed, and which they are entitled to in view of the art, entry of this amendment and passage of this application to issue with the claims as amended herein is earnestly solicited.

Applicants submit that the present application is in condition for allowance. In the event that minor amendments will further prosecution, Applicants request that the examiner contact the undersigned representative.

Respectfully submitted,



Kevin T. Mansfield
Agent for Applicants
Reg. No. 31,635

Ciba Specialty Chemicals Corporation
540 White Plains Road
Tarrytown, New York 10591
(914) 785-7127
KTM/221904A312

NOV 13 2003